A Phase 2 interventional study of Risankizumab and ABBV-295 in Moderate to Severe Psoriasis, sponsored by AbbVie. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Among 79 studies in Psoriasis by AbbVie — 2 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · AbbVie.
Among the 79 studies in Psoriasis by AbbVie, this one is the 36th largest by planned enrollment of the 48 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2, and was the 79th registered.
2,030 studies on the registry are indexed under Psoriasis; 277 are open to participants now.
Browse Psoriasis studies →2 of the 79 studies in Psoriasis by AbbVie are open now, in 8 countries. Recruiting first, the newest first:
AbbVie · Sites in Canada, Czechia, France and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 174 Psoriasis studies recruiting now, 91 (52%) set no upper age limit and 67 (39%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 31 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 166 across the 48 interventional studies, 246 across the 31 observational. Of the 71 that completed or were terminated, 42 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 976 studies on the registry; 135 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 214 (60%) have results posted.
1 of the studies in Psoriasis by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06247319AbbVieStudy to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 79 studies in Psoriasis by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Psoriasis is a long-term skin disease that causes inflammation, thick skin, and scaly patches on the skin. This study evaluates the safety and effectiveness of risankizumab in combination with ABBV-295 compared with risankizumab alone in adult participants with moderate to severe psoriasis.
Risankizumab is an approved drug for the treatment of moderate to severe psoriasis. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Participants will receive either risankizumab plus ABBV-295 or risankizumab plus ABBV-295 matching placebo. Around 105 adult participants with moderate to severe psoriasis will be enrolled in the study at approximately 50 sites worldwide.
Participants will receive injections of risankizumab and ABBV-295 or risankizumab and ABBV-295 matching placebo for up to 52 weeks, with a 20-week follow-up period after the last dose of the study.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive risankizumab in combinations with ABBV-295 for up to 52 weeks.
Drug: Risankizumab · Drug: ABBV-295
Participants will receive risankizumab with ABBV-295 matching placebo for up to 52 weeks.
Drug: Risankizumab · Drug: ABBV-295 Placebo
Injection
Injection
Injection
Percentage of Participants Achieving at least a 90% reduction from Baseline in Psoriasis Area and Severity Index (PASI 90)
PASI is a measure of psoriatic disease severity taking into account the overall severity of erythema, induration and scaling, and the extent of affected area in each of four anatomical regions (head, trunk, upper extremities, and lower extremities). PASI scores range from 0 (no psoriasis) to 72 (severe disease over the entire body surface). Higher scores indicate worse disease severity. PASI 90 indicates at least 90% improvement from baseline.
Time frame: Week 28
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to 72 Weeks
Percentage of Participants Achieving 100% Reduction from Baseline in PASI 100
PASI is a measure of psoriatic disease severity taking into account the overall severity of erythema, induration and scaling, and the extent of affected area in each of four anatomical regions (head, trunk, upper extremities, and lower extremities). PASI scores range from 0 (no psoriasis) to 72 (severe disease over the entire body surface). Higher scores indicate worse disease severity. PASI 100 indicates at least 100% improvement from baseline.
Time frame: Week 28
Percentage of Participants Achieving ≥10% Body Weight Reduction from Baseline
Achievement of at least 10% body weight reduction from Baseline.
Time frame: Week 28
Percent Change from Baseline in Body Weight
Percent change from Baseline in body weight.
Time frame: Week 28
No study locations are listed for this record.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 24 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABBV-295